{
    "clinical_study": {
        "@rank": "97488", 
        "acronym": "HAV", 
        "arm_group": [
            {
                "arm_group_label": "Attenuated HAV Vaccine, H2 Strain", 
                "arm_group_type": "Experimental", 
                "description": "6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-15 years \\6.50 lgCCID50/ml in adults aged 16 up to 65 years old"
            }, 
            {
                "arm_group_label": "Attenuated HAV Vaccine, L-A-1 Strain", 
                "arm_group_type": "Experimental", 
                "description": "6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose)."
            }, 
            {
                "arm_group_label": "Inactivated HAV Vaccine, Lu8 Strain", 
                "arm_group_type": "Experimental", 
                "description": "320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose"
            }, 
            {
                "arm_group_label": "Inactivated HAV Vaccine, TZ84 Strain", 
                "arm_group_type": "Experimental", 
                "description": "250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this Phase 4 trial is to assess the safety, immunogenicity, three-year immune\n      persistence of inactivated hepatitis A vaccine (HAV) and live attenuated HAV vaccine."
        }, 
        "brief_title": "The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis A", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hepatitis A refers to liver inflammation caused by infection with the hepatitis A virus. HAV\n      is is one of the most common hepatitis viruses that can cause hepatitis in China. The data\n      from the phase 1, 2 and 3 trials suggested that both inactivated hepatitis A vaccine and\n      live attenuated hepatitis A vaccine had a clinically acceptable safety and good\n      immunogenicity for healthy Chinese people."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Only subjects fulfilling all of the following criteria will be eligible for the\n             study:\n\n               -  People aged from 18 months to 65 years old.\n\n               -  The subjects or subjects' guardians are able to understand and sign the informed\n                  consent\n\n               -  The subjects or subjects' guardians allow to comply with the requirements of the\n                  protocol\n\n               -  Subjects with temperature <=37.0\u00b0C on axillary setting\n\n               -  The subjects have signed informed consent already\n\n        Exclusion Criteria:\n\n          -  Subjects will not be eligible for the study if any of the following criteria is met:\n\n               -  Subject who has a medical history of serious disease including Tumor, autoimmune\n                  disease, progressive atherosclerosis diseases or complications of diabetes,\n                  chronic obstructive pulmonary disease (copd), kidney disease, congestive heart\n                  failure etc.\n\n               -  Have a history of neurological symptoms or signs\n\n               -  Have medical history or family history relating to allergies, seizures,\n                  epilepsy, brain and spirit etc.\n\n               -  Suffering from serious chronic diseases\n\n               -  Suffering from known or suspected of diseases including respiratory diseases,\n                  acute infection , mothers have HIV infection, cardiovascular disease, severe\n                  hypertension, skin diseases, malignant tumor\n\n               -  Allergic to any ingredient in research, history of allergies to any vaccination\n                  (always), especially for people allergic to high protein food like eggs and milk\n\n               -  Any prior known or suspected damage or abnormal immune function. As for patients\n                  who are treated with immune inhibitors or immune enhancer medicine, accept with\n                  immunoglobin, blood products and plasma extraction within 3 months\n\n               -  Any prior diseases including human immunodeficiency virus infection or related\n\n               -  Bleeding constitution or prolong bleeding time situation\n\n               -  Accept hepatitis A vaccination within a month\n\n               -  Received vaccines, other immune globulin, any research drug injections in the\n                  past 4 weeks\n\n               -  People who had any acute illness, needed systemic antibiotics or antiviral\n                  treatment in the past 7 days\n\n               -  Caught a fever with axillary temperature 38\u00b0C or higher in past 3 days\n\n               -  Take part in another clinical researchers\n\n               -  Any medical, psychiatric, social condition, occupational reason or other\n                  responsibility that, in the judgment of the investigator, is a contraindication\n                  to protocol participation or impairs a volunteer's ability to give informed\n                  consent\n\n               -  Pregnancy test result is positive"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Months"
        }, 
        "enrollment": {
            "#text": "6000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949857", 
            "org_study_id": "qiangmingsun123456!"
        }, 
        "intervention": [
            {
                "arm_group_label": "Attenuated HAV Vaccine, H2 Strain", 
                "description": "6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).", 
                "intervention_name": "Attenuated HAV Vaccine, H2 Strain", 
                "intervention_type": "Biological", 
                "other_name": "Hepatitis A (Live) Vaccine, Freeze-dried"
            }, 
            {
                "arm_group_label": "Attenuated HAV Vaccine, L-A-1 Strain", 
                "description": "6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).", 
                "intervention_name": "Attenuated HAV Vaccine, L-A-1 Strain", 
                "intervention_type": "Biological", 
                "other_name": "Hepatitis A Vaccine"
            }, 
            {
                "arm_group_label": "Inactivated HAV Vaccine, Lu8 Strain", 
                "description": "320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose", 
                "intervention_name": "Inactivated HAV Vaccine, Lu8 Strain", 
                "intervention_type": "Biological", 
                "other_name": "Hepatitis A Vaccine, Inactivated"
            }, 
            {
                "arm_group_label": "Inactivated HAV Vaccine, TZ84 Strain", 
                "description": "250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose.", 
                "intervention_name": "Inactivated HAV Vaccine, TZ84 Strain", 
                "intervention_type": "Biological", 
                "other_name": "Hepatitis A Vaccine, Inactivated"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis A", 
            "Vaccine", 
            "Safety", 
            "efficacy"
        ], 
        "lastchanged_date": "September 20, 2013", 
        "location": {
            "contact": {
                "email": "qiangmingsun@gmail.com", 
                "last_name": "Qiangming Sun, Ph.D.", 
                "phone": "86-871-68335165"
            }, 
            "facility": {
                "address": {
                    "city": "Kunming", 
                    "country": "China", 
                    "state": "Yunnan", 
                    "zip": "650118"
                }, 
                "name": "Institute of Medical Biology -Chinese Academy of Medical Sciences"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase 4 Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine", 
        "overall_contact": {
            "email": "qiangmingsun@gmail.com", 
            "last_name": "Qiangming Sun, Ph.D.", 
            "phone": "86-871-68335165"
        }, 
        "overall_official": [
            {
                "affiliation": "Institude of Medical Biology, Chinese Academy of Medical Sciences", 
                "last_name": "Qihan Li, Ph.D.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Institude of Medical Biology, Chinese Academy of Medical Sciences", 
                "last_name": "Jingsi Yang", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Institude of Medical Biology, Chinese Academy of Medical Sciences", 
                "last_name": "Qiangming Sun, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Jiangsu Provincial Center for Disease Control and Prevention", 
                "last_name": "Fubao Ma", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "1. Changes of anti-HAV antibody geometric mean concentrations at pre-vaccination, month 1,12, 24, 36, and 1 months after the booster vaccination.", 
            "measure": "changes of hepatitis A antibody concentration", 
            "safety_issue": "No", 
            "time_frame": "up to 43 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949857"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Qiangming Sun", 
            "investigator_title": "Molecular Epidemiology Joint Laboratory", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "compare frequency of all the solicited events, unsolicited adverse events and serious adverse events between vaccine group and placebo group.", 
            "measure": "The frequency of all the adverse events in vaccine group and placebo group", 
            "safety_issue": "Yes", 
            "time_frame": "up to 43 months"
        }, 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "collaborator": {
                "agency": "Jiangsu Province Centers for Disease Control and Prevention", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}